(Q35882269)

10 August 2017

Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE (English)

1 reference

10 August 2017

0 references

1

Bernd C Kieseier

1 reference

10 August 2017

3

Laura J Balcer

1 reference

10 August 2017

12

Peter A Calabresi

1 reference

10 August 2017

9

Serena Hung

1 reference

10 August 2017

8

Ali Seddighzadeh

1 reference

10 August 2017

Douglas L Arnold

2

1 reference

10 August 2017

Alexey A Boyko

4

1 reference

10 August 2017

Jean Pelletier

5

1 reference

10 August 2017

Shifang Liu

6

1 reference

10 August 2017

Ying Zhu

7

1 reference

10 August 2017

Aaron Deykin

10

1 reference

10 August 2017

Sarah I Sheikh

11

1 reference

10 August 2017

28 November 2014

1 reference

Multiple Sclerosis Journal

10 August 2017

1 reference

10 August 2017

21

1 reference

10 August 2017

8

1 reference

10 August 2017

1025-1035

1 reference

Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study

10 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4512519

PEGylation of Interferon-β-1a

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4512519

Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4512519

PEGylation: an approach for drug delivery. A review

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4512519

N-terminally PEGylated human interferon-beta-1a with improved pharmacokinetic properties and in vivo efficacy in a melanoma angiogenesis model.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4512519

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4512519

Immunogenicity of interferon beta: differences among products

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4512519

Pharmacokinetic and biodistribution properties of poly(ethylene glycol)–protein conjugates

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4512519

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4512519

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4512519

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4512519

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4512519

The impact of neutralizing antibodies on the risk of disease worsening in interferon β-treated relapsing multiple sclerosis: a 5 year post-marketing study

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4512519

A novel PEGylated interferon beta-1a for multiple sclerosis: safety, pharmacology, and biology.

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4512519

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

24 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1177%2F1352458514557986

Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25432952

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25432952

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25432952

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1177/1352458514557986

1 reference

10 August 2017

1 reference

10 August 2017

1 reference